Evidence of a threshold-effect for 2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline liver carcinogenicity in F344/DuCrj rats. 2008

Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
Developmental Research Laboratories, Shionogi & Co., Ltd. 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan.

To estimate potential human risk of exposure to a food-derived, genotoxic hepatocarcinogen, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), a 2-year carcinogenicity test was conducted using male F344 rats administered MeIQx-containing diet at doses of 0 (control), 0.001, 1, and 100 ppm. The lowest dose 0.001 ppm was established as equivalent to the daily intake of this carcinogen in humans (0.2 to 2.6 microg/man/day). Significant decreases of survival rate and body weight gain were observed in rats treated with 100 ppm MeIQx. Histopathological examination revealed significant induction of hepatocellular carcinomas, adenomas, and development of glutathione S-transferase placental form-positive foci with MeIQx at 100 ppm. Moreover, the incidences of Zymbal's glands carcinoma, mammary fibroadenoma, and subcutaneous fibroma were found significantly increased in a 100 ppm MeIQx group. However, no significant induction of altered preneoplastic hepatocellular foci was observed in 0.001 and 1 ppm groups as compared to the controls. 8-Hydroxy-2'-deoxyguanosine levels in the rat liver DNA of the 100 ppm-treated group were not elevated, but MeIQx-DNA adduct formation increased as compared with the 1 ppm case, albeit without significance. No significant induction of any other neoplastic lesions related to the carcinogen administration was found in MeIQx-administered groups except for 100 ppm. These results imply that 1 ppm may be a no-effect level for MeIQx carcinogenesis.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008136 Longevity The normal length of time of an organism's life. Length of Life,Life Span,Lifespan,Life Spans,Lifespans
D008297 Male Males
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011810 Quinoxalines Quinoxaline
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D003849 Deoxyguanosine A nucleoside consisting of the base guanine and the sugar deoxyribose.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
January 1988, Carcinogenesis,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
January 1993, IARC monographs on the evaluation of carcinogenic risks to humans,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
January 1986, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
June 1999, Japanese journal of cancer research : Gann,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
May 1987, Carcinogenesis,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
September 1999, Cancer letters,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
May 1999, Cancer letters,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
November 2005, Cancer science,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
May 1992, Carcinogenesis,
Takshi Murai, and Satoru Mori, and Jin Seok Kang, and Keiichirou Morimura, and Hideki Wanibuchi, and Yukari Totsuka, and Shoji Fukushima
July 1989, Carcinogenesis,
Copied contents to your clipboard!